TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
The Pharma Data
JULY 11, 2021
Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Markus Magerl, M.D., At Takeda we are a committed champion for the patients we serve. Contraindication. Interactions.
Let's personalize your content